Medscape

First-in-Class COPD Drug Eases Symptoms

PARIS — A first-in-class dual PDE3/4 inhibitor significantly improves bronchodilation and symptoms in patients with chronic obstructive pulmonary disease (COPD), results from a phase 2 multicenter ...
Monthly Prescribing Reference

First-in-Class Dual PDE Inhibitor Plus Tiotropium May Improve Lung Function in COPD

Nebulized ensifentrine, when added to tiotropium, produced clinically meaningful and significant improvements in lung function and quality of life in patients with COPD. This article is part of MPR’s ...
Healthline

New and Current Treatments for COPD

There’s no cure for chronic obstructive pulmonary disease (COPD), but treatment can help manage symptoms over time. Doctors often combine medications with lifestyle changes like quitting smoking.
Benzinga.com

Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug

Merck & Co. Inc. (NYSE:MRK) agreed on Wednesday to acquire Verona Pharma plc (NASDAQ:VRNA) for $107 per American Depository Share (ADS) for a total transaction value of approximately $10 billion. Each ...